Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIMP3 | P35625 | 6/20 | 1.00 |
| ▸ | RECQL | P46063 | 6/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.71 |
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | PKM | P14618 | 5/20 | 0.71 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.71 |
| ▸ | APEX1 | P27695 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | POLB | P06746 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.71 |
| ▸ | BLM | P54132 | 4/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.71 |
| ▸ | BRCA1 | P38398 | 3/20 | 0.71 |
| ▸ | STAT1 | P42224 | 3/20 | 0.71 |
| ▸ | STAT5A | P42229 | 3/20 | 0.71 |
| ▸ | STAT5B | P51692 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12410284 | 0.93 | TIMP3 (0.86) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL21645072 | 0.92 | RECQL (0.86) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL12410283 | 0.87 | TIMP3 (0.75) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL16921052 | 0.87 | TIMP3 (0.75) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL12903191 | 0.85 | TIMP3 (0.72) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL14506109 | 0.82 | TIMP3 (0.67) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL14015896 | 0.82 | TIMP3 (0.67) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL11596825 | 0.80 | TIMP3 (0.67) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL11595757 | 0.80 | TIMP3 (0.67) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL27141426 | 0.79 | TIMP3 (0.65) | TIMP3RECQLKMT2AHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057331-A1 | NOVEL CELLULAR TARGETS FOR HIV INFECTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2015-02-26 | — | — | US | claimed |
| US-20140123342-A1 | Regulation of Stomatal Apertures by Apyrases and Extracellular Nucleotides | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-05-01 | — | — | US | claimed |
| US-20130150410-A1 | Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-13 | — | — | US | claimed |
| US-8399018-B2 | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2013-03-19 | — | — | US | claimed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2021-05-13 | — | — | US | disclosed |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | OTONOMY INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200230051-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. | 2020-07-23 | — | — | US | disclosed |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | THE BURNHAM INSTITUTE (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | THE BURNHAM INSTITUTE (US) | 2009-05-07 | — | — | US | disclosed |
| EP-2049127-A2 | N-METHANOCARBA DERIVATIVES TO TREAT CARDIAC DISEASES | University of Connecticut (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2007139775-A2 | N-METHANOCARBA DERIVATIVES TO TREAT CARDIAC DISEASES | UNIVERSITY OF CONNECTICUT (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281908-A1 | COMPOSITION AND METHODS TO TREAT CARDIAC DISEASES | UNIVERSITY OF CONNECTICUT (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070099863-A1 | Compounds for the treatment of demyelinating and autoimmune diseases | UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO (ES) | 2007-05-03 | — | — | US | disclosed |
| US-20070099863-A1 | Compounds for the treatment of demyelinating and autoimmune diseases | UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO (ES) | 2007-05-03 | — | — | US | disclosed |
| EP-1655032-A1 | COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE AND DEMYELINATING DISEASES | UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO UNIBERSITATEA (ES) | 2006-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150410-A1 | Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders | TRPV1, ATP2A1, TRPM2 | TIMP3 2109/4885RECQL 479/4885KMT2A 3763/4885 |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | TIMP3 1503/4885RECQL 1042/4885KMT2A 3482/4885 |
| US-20070281908-A1 | COMPOSITION AND METHODS TO TREAT CARDIAC DISEASES | P2RX2, P2RX3, ATP2A1 | TIMP3 2113/4885RECQL 2228/4885KMT2A 3338/4885 |
| US-20070099863-A1 | Compounds for the treatment of demyelinating and autoimmune diseases | P2RX2, P2RX3, P2RX1 | TIMP3 3417/4885RECQL 902/4885KMT2A 3058/4885 |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | TIMP3 776/4885RECQL 1250/4885KMT2A 3984/4885 |
| US-20200230051-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | TIMP3 776/4885RECQL 1250/4885KMT2A 3984/4885 |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | TIMP3 1250/4885RECQL 1038/4885KMT2A 3688/4885 |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTC, AQP4, SLC26A4 | TIMP3 776/4885RECQL 1250/4885KMT2A 3984/4885 |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | BCL2, BAX, BAD | TIMP3 1326/4885RECQL 3059/4885KMT2A 4047/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | TIMP3 1503/4885RECQL 1042/4885KMT2A 3482/4885 |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | TIMP3 1250/4885RECQL 1038/4885KMT2A 3688/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | TIMP3 776/4885RECQL 1250/4885KMT2A 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.